



ABIVAX to present at the prestigious Conference on Retroviruses and Opportunistic Infections (CROI) positive top-line clinical Phase IIa data for novel HIV drug-candidate ABX464

Abstract accepted as a late-breaking news presentation

Paris, France January 21st 2016 – ABIVAX (Euronext Paris: FR0012333284 – ABVX), an emerging leader in developing and commercializing novel antiviral therapies for diseases like HIV/AIDS and chronic Hepatitis B (CHB), today announced the acceptance of the abstract "Early Evidence of Antiviral Activity & Safety of ABX464 in HIV Treatment Naive Patients," as a late-breaking news presentation by the prestigious Conference on Retroviruses and Opportunistic Infections (CROI), to be held February 22-25, 2016 in Boston, Massachusetts, at the Hynes Convention Center.

Top-line data from this Phase IIa dose-ranging trial in 80 patients were announced on January 11. At CROI, ABIVAX will present more detailed data from the study, in which a dose-dependent increase in response rate (viral load reduction of 0.5 log, i.e. 68% or greater) was observed, along with a strong safety profile. The presentation will be delivered by Dr. Jean-Marc Steens, Chief Medical Officer at ABIVAX, on February 25th from 2:45PM to 4:00 PM.

ABX464 is a first-in-class orally available antiviral drug candidate for the treatment of patients with HIV infection. It blocks HIV replication through a unique mechanism of action that leads to the destruction of viral RNA. Previously reported preclinical data in humanized mice demonstrated that ABX464 monotherapy had an antiviral effect which was sustained for at least 6 weeks following treatment interruption ([Campos et al, *Retrovirology* 2015, 12:30](#)).

ABIVAX (www.abivax.com) is an emerging global leader in the discovery, development and commercialization of anti-viral therapeutics and therapeutic vaccines to treat some of the world's most life-threatening infectious diseases, including HIV/AIDS and chronic Hepatitis B. ABIVAX has 2 compounds in clinical stage research: ABX464 a novel first-in-class resistance-proof oral small molecule HIV/AIDS therapy; and, ABX203, a therapeutic vaccine recently approved in Cuba and in late-stage clinical development in other countries that could cure chronic Hepatitis B. ABIVAX also is advancing additional anti-viral compounds and therapeutic vaccines that may enter the clinical stage in the coming 18 months. A recently updated corporate presentation, which includes a timeline for the company's anticipated news flow, is available at <http://www.abivax.com/en/>. Follow us on Twitter [@ABIVAX](https://twitter.com/ABIVAX)

Contacts:

Investor relations

Raquel Lizarraga
raquel.lizarraga@abivax.com
+33 1 53 83 09 63

Citigate Dewe Rogerson

Lucie Larguier
abivax@citigate.fr
+33 1 53 32 84 75

Life Sci Advisors

Chris Maggos
chris@lifesciadvisors.com
+41 79 367 6254

Press relations

ALIZE RP

Caroline Carmagnol and Florence Portejoie
abivax@alizerp.com
+33 6 64 18 99 59 / + 33 1 44 54 36 64